Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

Authors

Natasha Rekhtman, Matthew G Hanna, Paul Hofman, Mari Mino-Kenudson, Philippe Joubert, Mauro Papotti, Lynette M Sholl, Hyo Sup Shim, Yuchen Han, Véronique Hofman, Yin P Hung, Marina K Baine, Rania G Aly, Deepali Jain, Teodora Radonic, Anjali Saqi, Mary Beth Beasley, Jin-Haeng Chung, Wendy Cooper, Fred R Hirsch, Keith Kerr, Sylvie Lantuejoul, Daisuke Matsubara, Noriko Motoi, Andrew G Nicholson, William D Travis, Jan von der Thüsen, Yasushi Yatabe, Anja C Roden

Published in

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Pages 106121. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Lung carcinoids are well-differentiated neuroendocrine tumors (NETs), designated in the current thoracic WHO classification as typical carcinoids (grade 1) and atypical carcinoids (grade 2), whereas rare tumors with carcinoid/NET morphology and >10 mitoses/2mm² are designated as large cell neuroendocrine carcinoma (LCNEC). This approach, however, has been a matter of growing debate.
Lung resections of tumors with carcinoid/NET morphology and >10 mitoses/2 mm² were contributed by the members of IASLC Pathology Committee. Digitized slides and detailed clinicopathologic, immunohistochemical, and molecular data were collected and analyzed.
In total, 28 cases meeting the study criteria were collected from 9 institutions in 6 countries. Tumors exhibited mean mitotic counts of 15/2mm² (range, 11-30/2mm²) and mean hot-spot Ki-67 rate of 32% (range 13-54%). In all cases, Ki-67 was heterogeneous, containing cold-spot zones with Ki-67 of <1%-15%. In all cases, Rb and p53 showed wild-type pattern by immunohistochemistry. Next-generation sequencing (n=9) revealed wild-type RB1 and TP53, low TMB (1.3-3.3 mutations/Mb), and genomic alterations characteristic of lung carcinoids. The study cohort exhibited significantly worse OS and RFS than control groups of 117 typical and 52 atypical carcinoids (P<0.0001 for all comparisons).
In this international multi-institutional study, we address a major unresolved issue for WHO classification. By assembling the largest cohort to-date of the study cases, we propose that they should be classified as grade 3 carcinoids/NETs rather than LCNEC to enable clinical management more aligned with their biology. The concurrent IASLC proposal to include Ki-67 as additional criterion for grade 3 carcinoids should further enhance this approach.

PMID:
42790640
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.